Clinical Trials Logo

Breast Neoplasms clinical trials

View clinical trials related to Breast Neoplasms.

Filter by:

NCT ID: NCT05890677 Recruiting - Clinical trials for Lymphedema, Breast Cancer

The LYMPH Trial - Surgical Versus Conservative Complex Physical Decongestion Therapy for Chronic Breast Cancer-Related Lymphedema

LYMPH
Start date: July 14, 2023
Phase: N/A
Study type: Interventional

The aim of this study is to test whether lymphatic surgery provides better QoL (assessed with the Lymph-ICF-UL, (Lymphedema Functioning Disability and health questionnaire for upper limb lymphedema)) 15 months after randomization (and therefore about one year after surgery) compared to conservative treatment only for patients with chronic lymphedema (LE)

NCT ID: NCT05890287 Recruiting - Clinical trials for HR Positive HER2 Negative Advanced Breast Cancer

A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy

Start date: May 16, 2023
Phase: N/A
Study type: Interventional

To explore the efficacy and safety of Chidamide combined with endocrine for maintenance therapy after first-line chemotherapy for HR+/HER2- breast cancer

NCT ID: NCT05889988 Recruiting - Breast Neoplasm Clinical Trials

A Study of Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients

Start date: June 12, 2023
Phase:
Study type: Observational

Researchers plan to study the natural history of ado-trastuzumab emtansine (T-DM1)-induced neuropathy both in patients without any history of neuropathy or previous neurotoxic agent use and in patients who have such a history.

NCT ID: NCT05889728 Recruiting - Breast Cancer Clinical Trials

Pilot Trial to Assess 68Ga Bombesin PET/CT (NeoB) Imaging for Staging of Breast Cancer

Start date: February 20, 2023
Phase: Phase 2
Study type: Interventional

This phase IIb pilot study will enrol 20 patients (women) presenting with metastatic breast cancer (ER/PR + HER2- on histology) who require imaging for staging or re-staging of their disease.

NCT ID: NCT05889390 Recruiting - Clinical trials for HER2-negative Breast Cancer

Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer

NeoHTerMa
Start date: February 20, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The aim of this study is to investigate whether the application of concomitant modulated electro-hyperthermia in a neoadjuvant chemotherapeutic setting is beneficial for patients with HER2-negative, stage II-III breast cancer.

NCT ID: NCT05887102 Recruiting - Breast Cancer Clinical Trials

Pilot Study of PACHA Program to Enhance Adherence to Adjuvant Endocrine Therapy Among Breast Cancer Survivors

PACHA
Start date: June 7, 2023
Phase: N/A
Study type: Interventional

The goal of this randomized controlled pilot study is to assess the feasibility, acceptability, and preliminary effects of the PACHA program designed for women having an adjuvant endocrine therapy (AET) after hormone-sensitive breast cancer. PACHA (programme en Pharmacie pour l'ACcompagnement des femmes ayant de l'Hormonothérapie Adjuvante) is a community pharmacy-based program aimed at optimizing the experience of AET and its use. The main questions it aims to answer are : - Does the program have an effect on factors expected to influence AET adherence? - Is the program acceptable? - Is the implementation of the program feasible? - What is the feasibility of procedures for carrying out a full-scale study? Participating community pharmacies will be randomized. Pharmacists working in pharmacies assigned to the PACHA group (33 pharmacies) will receive web-based training and manuals to use during their consultations with women having an AET. Recruited women attending these pharmacies will also have access to information and resources about AET (videos, evidence-based booklet). Pharmacists practicing in pharmacies assigned to the control group (33 pharmacies) will provide usual care.

NCT ID: NCT05885776 Recruiting - Breast Cancer Clinical Trials

Preoperative Treatment of HR+/HER2+Breast Cancer With Pirotinib, Trastuzumab and AI Research

PYTHON
Start date: September 13, 2022
Phase: Phase 2
Study type: Interventional

Research topic Preoperative efficacy and safety of pyrrolitinib combined with trastuzumab and AI in the treatment of HR+/HER2+breast cancer Overall: A single arm multicenter phase II exploratory study。Subjects HR+/HER2+breast cancer patients in stage Ⅱ~Ⅲ A。

NCT ID: NCT05883852 Recruiting - Clinical trials for HER2 Positive Early Breast Cancer

EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer

Start date: June 7, 2023
Phase: Phase 3
Study type: Interventional

compare the efficacy and safety of TCbHP and EC-THP regimen in HER2-positive breast cancer patients

NCT ID: NCT05880927 Recruiting - Breast Cancer Clinical Trials

Pyrotinib After Trastuzumab-based Adjuvant Therapy in Patients With HER2-positive Breast Cancer

Start date: January 1, 2019
Phase: Phase 2
Study type: Interventional

This trial is a multicenter, open-label, phase II trial conducted at 23 centers in China. High-risk HER2 positive patients receive pyrotinib 400mg/day for one year or half year for extented adjuvant therapy.

NCT ID: NCT05879926 Recruiting - Breast Cancer Clinical Trials

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

OFSET
Start date: August 31, 2023
Phase: Phase 3
Study type: Interventional

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).